{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T05:47:49Z","timestamp":1782884869467,"version":"3.54.5"},"reference-count":233,"publisher":"Elsevier","isbn-type":[{"value":"9780128166680","type":"print"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/bs.apha.2019.05.001","type":"book-chapter","created":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T20:48:05Z","timestamp":1563828485000},"page":"153-196","source":"Crossref","is-referenced-by-count":19,"title":["Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders"],"prefix":"10.1016","author":[{"given":"Laura B.","family":"Teal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Gould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Felts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie K.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.apha.2019.05.001_bb0010","series-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nn992","article-title":"Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice","volume":"6","author":"Anagnostaras","year":"2003","journal-title":"Nature Neuroscience"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb0020","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2156-8-46","article-title":"Variation in the gene coding for the M5 muscarinic receptor (CHRM5) influences cigarette dose but is not associated with dependence to drugs of addiction: Evidence from a prospective population based cohort study of young adults","volume":"8","author":"Anney","year":"2007","journal-title":"BMC Genetics"},{"issue":"9","key":"10.1016\/bs.apha.2019.05.001_bb0025","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1017\/S1461145710001549","article-title":"The M1\/M4 preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: Putative efficacy against positive, negative and cognitive symptoms in schizophrenia","volume":"14","author":"Barak","year":"2011","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"17","key":"10.1016\/bs.apha.2019.05.001_bb0030","doi-asserted-by":"crossref","first-page":"11452","DOI":"10.1073\/pnas.162371899","article-title":"Deletion of the M5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia","volume":"99","author":"Basile","year":"2002","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.apha.2019.05.001_bb0035","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1038\/emboj.2010.154","article-title":"AGAP1\/AP-3-dependent endocytic recycling of M5 muscarinic receptors promotes dopamine release","volume":"29","author":"Bendor","year":"2010","journal-title":"The EMBO Journal"},{"issue":"4","key":"10.1016\/bs.apha.2019.05.001_bb0040","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1124\/mol.116.104182","article-title":"Molecular mechanisms of action of M5 muscarinic acetylcholine receptor allosteric modulators","volume":"90","author":"Berizzi","year":"2016","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/bs.apha.2019.05.001_bb0045","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1038\/s41386-017-0007-3","article-title":"Muscarinic M5 receptors modulate ethanol seeking in rats","volume":"43","author":"Berizzi","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/bs.apha.2019.05.001_bb0050","doi-asserted-by":"crossref","first-page":"215","DOI":"10.31887\/DCNS.2007.9.2\/jbobes","article-title":"Quality of life in schizophrenic patients","volume":"9","author":"Bobes","year":"2007","journal-title":"Dialogues in Clinical Neuroscience"},{"key":"10.1016\/bs.apha.2019.05.001_bb0055","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.neuropharm.2017.09.024","article-title":"Allosteric modulators targeting CNS muscarinic receptors","volume":"136","author":"Bock","year":"2018","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/bs.apha.2019.05.001_bb0060","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","article-title":"Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease","volume":"54","author":"Bodick","year":"1997","journal-title":"Archives of Neurology"},{"issue":"Suppl. 4","key":"10.1016\/bs.apha.2019.05.001_bb0065","first-page":"S16","article-title":"The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease","volume":"11","author":"Bodick","year":"1997","journal-title":"Alzheimer Disease and Associated Disorders"},{"issue":"2","key":"10.1016\/bs.apha.2019.05.001_bb0070","first-page":"576","article-title":"Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells","volume":"260","author":"Bolden","year":"1992","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"3","key":"10.1016\/bs.apha.2019.05.001_bb0075","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1124\/jpet.108.140350","article-title":"Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats","volume":"327","author":"Brady","year":"2008","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.apha.2019.05.001_bb0080","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pnpbp.2013.11.008","article-title":"Predictive validity of a MK-801-induced cognitive impairment model in mice: Implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically","volume":"49","author":"Brown","year":"2014","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1016\/bs.apha.2019.05.001_bb0085","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.schres.2017.06.039","article-title":"Demographic and clinical correlates of substance use disorders in first episode psychosis","volume":"194","author":"Brunette","year":"2018","journal-title":"Schizophrenia Research"},{"issue":"10","key":"10.1016\/bs.apha.2019.05.001_bb0090","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1021\/cn500128b","article-title":"Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents","volume":"5","author":"Bubser","year":"2014","journal-title":"ACS Chemical Neuroscience"},{"issue":"12","key":"10.1016\/bs.apha.2019.05.001_bb0095","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1523\/JNEUROSCI.08-12-04646.1988","article-title":"Localization of a family of muscarinic receptor mRNAs in rat brain","volume":"8","author":"Buckley","year":"1988","journal-title":"The Journal of Neuroscience"},{"issue":"2","key":"10.1016\/bs.apha.2019.05.001_bb0100","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/schbul\/sbn135","article-title":"Psychiatric comorbidities and schizophrenia","volume":"35","author":"Buckley","year":"2009","journal-title":"Schizophrenia Bulletin"},{"issue":"10","key":"10.1016\/bs.apha.2019.05.001_bb0105","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1085\/jgp.201711979","article-title":"Toward an understanding of the structural basis of allostery in muscarinic acetylcholine receptors","volume":"150","author":"Burger","year":"2018","journal-title":"The Journal of General Physiology"},{"key":"10.1016\/bs.apha.2019.05.001_bb0110","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"2","key":"10.1016\/bs.apha.2019.05.001_bb0115","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/(SICI)1098-2299(199702)40:2<158::AID-DDR6>3.0.CO;2-K","article-title":"Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease","volume":"40","author":"Bymaster","year":"1997","journal-title":"Drug Development Research"},{"issue":"7","key":"10.1016\/bs.apha.2019.05.001_bb0120","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1038\/npp.2014.2","article-title":"Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100","volume":"39","author":"Byun","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.apha.2019.05.001_bb0125","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1111\/j.1460-9568.1998.00294.x","article-title":"Endogenous ACh enhances striatal NMDA-responses via M1-like muscarinic receptors and PKC activation","volume":"10","author":"Calabresi","year":"1998","journal-title":"European Journal of Neuroscience"},{"key":"10.1016\/bs.apha.2019.05.001_bb0130","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fgene.2016.00149","article-title":"Associations between polygenic risk for -psychiatric disorders and substance involvement","volume":"7","author":"Carey","year":"2016","journal-title":"Frontiers in Genetics"},{"issue":"7","key":"10.1016\/bs.apha.2019.05.001_bb0135","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00406-012-0305-z","article-title":"The lifetime and past-year prevalence of dual diagnosis in people with schizophrenia across Europe: Findings from the European Schizophrenia Cohort (EuroSC)","volume":"262","author":"Carr\u00e0","year":"2012","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"4","key":"10.1016\/bs.apha.2019.05.001_bb0140","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s00213-006-0671-1","article-title":"Behavioral effects of morphine and cocaine in M1 muscarinic acetylcholine receptor-deficient mice","volume":"191","author":"Carrigan","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.apha.2019.05.001_bb0145","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pscychresns.2018.08.014","article-title":"The effects of a muscarinic receptor 1 gene variant on cortical thickness and surface area in schizophrenia","volume":"280","author":"Carruthers","year":"2018","journal-title":"Psychiatry Research: Neuroimaging"},{"issue":"2","key":"10.1016\/bs.apha.2019.05.001_bb0150","first-page":"279","article-title":"International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors","volume":"50","author":"Caulfield","year":"1998","journal-title":"Pharmacological Reviews"},{"issue":"1\u20133","key":"10.1016\/bs.apha.2019.05.001_bb0155","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejphar.2012.10.011","article-title":"Using cholinergic M1 receptor positive allosteric modulators to improve memory via enhancement of brain cholinergic communication","volume":"697","author":"Chambon","year":"2012","journal-title":"European Journal of Pharmacology"},{"issue":"31","key":"10.1016\/bs.apha.2019.05.001_bb0160","doi-asserted-by":"crossref","first-page":"10978","DOI":"10.1073\/pnas.0800567105","article-title":"Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia","volume":"105","author":"Chan","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1016\/bs.apha.2019.05.001_bb0165","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1124\/jpet.116.235788","article-title":"Positive allosteric modulation of the muscarinic M1 receptor improves efficacy of antipsychotics in mouse glutamatergic deficit models of behavior","volume":"359","author":"Choy","year":"2016","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.apha.2019.05.001_bb0170","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nrd746","article-title":"Allosteric binding sites on cell-surface receptors: Novel targets for drug discovery","volume":"1","author":"Christopoulos","year":"2002","journal-title":"Nature Reviews Drug Discovery"},{"issue":"3","key":"10.1016\/bs.apha.2019.05.001_bb0175","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/0306-4522(87)90176-X","article-title":"Innervation of substantia nigra neurons by cholinergic afferents from pedunculopontine nucleus in the rat: Neuroanatomical and electrophysiological evidence","volume":"23","author":"Clarke","year":"1987","journal-title":"Neuroscience"},{"key":"10.1016\/bs.apha.2019.05.001_bb0180","series-title":"Pilot study comparing effects of xanomeline alone to xanomeline plus trospium","author":"ClinicalTrials.gov","year":"2017"},{"key":"10.1016\/bs.apha.2019.05.001_bb0185","series-title":"A study to assess safety and efficacy of KarXT in adult patients with schizophrenia","author":"ClinicalTrials.gov","year":"2018"},{"issue":"9","key":"10.1016\/bs.apha.2019.05.001_bb0190","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nrd4308","article-title":"Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders","volume":"13","author":"Conn","year":"2014","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"3","key":"10.1016\/bs.apha.2019.05.001_bb0195","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s13311-017-0525-z","article-title":"Reward circuitry in addiction","volume":"14","author":"Cooper","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"19","key":"10.1016\/bs.apha.2019.05.001_bb0200","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0024-3205(99)00114-9","article-title":"The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia","volume":"64","author":"Crook","year":"1999","journal-title":"Life Sciences"},{"issue":"5","key":"10.1016\/bs.apha.2019.05.001_bb0205","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0006-3223(00)00918-5","article-title":"Decreased muscarinic receptor binding in subjects with schizophrenia: A study of the human hippocampal formation","volume":"48","author":"Crook","year":"2000","journal-title":"Biological Psychiatry"},{"key":"10.1016\/bs.apha.2019.05.001_bb0210","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1176\/appi.ajp.158.6.918","article-title":"Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: A study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment","volume":"158","author":"Crook","year":"2001","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1016\/bs.apha.2019.05.001_bb0215","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.pscychresns.2015.09.004","article-title":"The effect of a muscarinic receptor 1 gene variant on grey matter volume in schizophrenia","volume":"234","author":"Cropley","year":"2015","journal-title":"Psychiatry Research: Neuroimaging"},{"key":"10.1016\/bs.apha.2019.05.001_bb0220","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.drugalcdep.2017.03.014","article-title":"Muscarinic receptor M4 positive allosteric modulators attenuate central effects of cocaine","volume":"176","author":"Dall","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"issue":"6","key":"10.1016\/bs.apha.2019.05.001_bb0225","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1152\/jn.1997.77.6.2975","article-title":"Excitation of the brain stem pedunculopontine tegmentum cholinergic cells induces wakefulness and REM sleep","volume":"77","author":"Datta","year":"1997","journal-title":"Journal of Neurophysiology"},{"issue":"13","key":"10.1016\/bs.apha.2019.05.001_bb0230","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1021\/acs.jmedchem.6b00544","article-title":"Discovery of the potent and selective M1 PAM-agonist N-[(3R,4S)-3-hydroxytetrahydro-2H -pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of efficacy and cholinergic side effects","volume":"59","author":"Davoren","year":"2016","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.apha.2019.05.001_bb0235","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000079102","article-title":"Linkage of M5 muscarinic and (alpha)7-nicotinic receptor genes on 15q13 to schizophrenia","volume":"50","author":"De Luca","year":"2004","journal-title":"Neuropsychobiology"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb0240","first-page":"54","article-title":"The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia","volume":"1","author":"Dean","year":"1996","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/bs.apha.2019.05.001_bb0245","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/sj.mp.4001199","article-title":"Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia","volume":"7","author":"Dean","year":"2002","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/bs.apha.2019.05.001_bb0250","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00213-012-2751-8","article-title":"An allosteric enhancer of M4 muscarinic acetylcholine receptor function inhibits behavioral and neurochemical effects of cocaine","volume":"224","author":"Dencker","year":"2012","journal-title":"Psychopharmacology"},{"issue":"16","key":"10.1016\/bs.apha.2019.05.001_bb0255","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.1523\/JNEUROSCI.0370-11.2011","article-title":"Involvement of a subpopulation of neuronal M4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1\/M4 preferring muscarinic receptor agonist xanomeline","volume":"31","author":"Dencker","year":"2011","journal-title":"The Journal of Neuroscience"},{"issue":"6","key":"10.1016\/bs.apha.2019.05.001_bb0260","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/jnr.20600","article-title":"Decreased density of muscarinic receptors in the superior temporal gyrusin schizophrenia","volume":"81","author":"Deng","year":"2005","journal-title":"Journal of Neuroscience Research"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb0265","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.coph.2006.11.003","article-title":"Reward system and addiction: What dopamine does and doesn't do","volume":"7","author":"Di Chiara","year":"2007","journal-title":"Current Opinion in Pharmacology"},{"issue":"14","key":"10.1016\/bs.apha.2019.05.001_bb0270","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1073\/pnas.85.14.5274","article-title":"Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats","volume":"85","author":"Di Chiara","year":"1988","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.apha.2019.05.001_bb0275","article-title":"Alterations in cortical interneurons and cognitive function in schizophrenia","author":"Dienel","year":"2018","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/bs.apha.2019.05.001_bb0280","first-page":"459","article-title":"Immunological detection of muscarinic receptor subtype proteins (m1-m5) in rabbit peripheral tissues","volume":"40","author":"Dorje","year":"1991","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/bs.apha.2019.05.001_bb0285","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.schres.2017.04.016","article-title":"The link between schizophrenia and substance use disorder: A unifying hypothesis","volume":"194","author":"Dwiel","year":"2018","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1016\/bs.apha.2019.05.001_bb0290","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0306-4522(88)90251-5","article-title":"An anatomical study of cholinergic innervation in rat cerebral cortex","volume":"25","author":"Eckenstein","year":"1988","journal-title":"Neuroscience"},{"issue":"8","key":"10.1016\/bs.apha.2019.05.001_bb0295","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1176\/ajp.138.8.1078","article-title":"Physostigmine and lithium response in the schizophrenias","volume":"138","author":"Edelstein","year":"1981","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb0300","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1601-183X.2012.00873.x","article-title":"Effects of cocaine and withdrawal on the mouse nucleus accumbens transcriptome","volume":"12","author":"Eipper-Mains","year":"2013","journal-title":"Genes, Brain and Behavior"},{"key":"10.1016\/bs.apha.2019.05.001_bb0305","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1146\/annurev.psych.48.1.649","article-title":"Central cholinergic system and cognition","volume":"48","author":"Everitt","year":"1997","journal-title":"Annual Review of Psychology"},{"key":"10.1016\/bs.apha.2019.05.001_bb0310","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/S0024-3205(01)01059-1","article-title":"Elucidating the role of muscarinic receptors in psychosis","volume":"68","author":"Felder","year":"2001","journal-title":"Life Sciences"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb0315","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0149-7634(85)90037-5","article-title":"Tolerance to the behavioral actions of benzodiazepines","volume":"9","author":"File","year":"1985","journal-title":"Neuroscience & Biobehavioral Reviews"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb0320","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/jnr.10728","article-title":"Role for M5 muscarinic acetylcholine receptors in cocaine addiction","volume":"74","author":"Fink-Jensen","year":"2003","journal-title":"Journal of Neuroscience Research"},{"key":"10.1016\/bs.apha.2019.05.001_bb0325","first-page":"736","article-title":"Interactions of cocaine with primary and secondary recognition sites on muscarinic receptors","volume":"41","author":"Flynn","year":"1992","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/bs.apha.2019.05.001_bb0330","first-page":"1","article-title":"M5 muscarinic receptors are required for prolonged accumbal dopamine release after electrical stimulation of the pons in mice","volume":"21","author":"Forster","year":"2001","journal-title":"The Journal of Neuroscience"},{"issue":"9","key":"10.1016\/bs.apha.2019.05.001_bb0335","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1523\/JNEUROSCI.4896-13.2014","article-title":"M5 receptor activation produces opposing physiological outcomes in dopamine neurons depending on the receptor's location","volume":"34","author":"Foster","year":"2014","journal-title":"Journal of Neuroscience"},{"issue":"6","key":"10.1016\/bs.apha.2019.05.001_bb0340","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.neuron.2016.08.017","article-title":"Antipsychotic-like effects of M4 positive allosteric modulators are mediated by CB2 receptor-dependent inhibition of dopamine release","volume":"91","author":"Foster","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/bs.apha.2019.05.001_bb0345","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000357682","article-title":"Effects of selective activation of M1 and M4 muscarinic receptors on object recognition memory performance in rats","volume":"93","author":"Galloway","year":"2014","journal-title":"Pharmacology"},{"issue":"13","key":"10.1016\/bs.apha.2019.05.001_bb0350","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1002\/cne.23323","article-title":"Somatodendritic targeting of M5 muscarinic receptor in the rat ventral tegmental area: Implications for mesolimbic dopamine transmission","volume":"521","author":"Garz\u00f3n","year":"2013","journal-title":"Journal of Comparative Neurology"},{"issue":"22","key":"10.1016\/bs.apha.2019.05.001_bb0355","doi-asserted-by":"crossref","first-page":"9351","DOI":"10.1021\/jm4013246","article-title":"Discovery of the first M5-selective and CNS penetrant negative allosteric modulator (NAM) of a muscarinic acetylcholine receptor: (S)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1 H -imidazo[2,1- a ]isoindol-5(9b H)-one (ML375)","volume":"56","author":"Gentry","year":"2013","journal-title":"Journal of Medicinal Chemistry"},{"issue":"26","key":"10.1016\/bs.apha.2019.05.001_bb0360","doi-asserted-by":"crossref","first-page":"15312","DOI":"10.1073\/pnas.261583798","article-title":"Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice","volume":"98","author":"Gerber","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1016\/bs.apha.2019.05.001_bb0365","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/npp.2015.189","article-title":"Potentiation of M1 muscarinic receptor reverses plasticity deficits and negative and cognitive symptoms in a schizophrenia mouse model","volume":"41","author":"Ghoshal","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb0370","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1476-5381.1986.tb11123.x","article-title":"Binding and functional profiles of the selective M1 muscarinic receptor antagonists trihexyphenidyl and dicyclomine","volume":"89","author":"Giachetti","year":"1986","journal-title":"British Journal of Pharmacology"},{"issue":"6","key":"10.1016\/bs.apha.2019.05.001_bb0375","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jpsychires.2004.04.005","article-title":"Impairment of visuospatial memory is associated with decreased slow wave sleep in schizophrenia","volume":"38","author":"G\u00f6der","year":"2004","journal-title":"Journal of Psychiatric Research"},{"issue":"10","key":"10.1016\/bs.apha.2019.05.001_bb0380","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1021\/acschemneuro.5b00123","article-title":"Role for the M1 muscarinic acetylcholine receptor in top-down cognitive processing using a touchscreen visual discrimination task in mice","volume":"6","author":"Gould","year":"2015","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/bs.apha.2019.05.001_bb0385","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.neuropharm.2017.07.013","article-title":"Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M4 PAM VU0467154","volume":"128","author":"Gould","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.apha.2019.05.001_bb0390","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.neuropharm.2015.11.016","article-title":"State-dependent alterations in sleep\/wake architecture elicited by the M4 PAM VU0467154\u2014Relation to antipsychotic-like drug effects","volume":"102","author":"Gould","year":"2016","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/bs.apha.2019.05.001_bb0395","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/0306-4522(89)90008-0","article-title":"Cholinergic projections to the substantia nigra from the pedunculopontine and laterodorsal tegmental nuclei","volume":"28","author":"Gould","year":"1989","journal-title":"Neuroscience"},{"issue":"12","key":"10.1016\/bs.apha.2019.05.001_bb0400","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1021\/acschemneuro.6b00230","article-title":"Prefrontal cortex-mediated impairments in a genetic model of NMDA receptor hypofunction are reversed by the novel M1 PAM VU6004256","volume":"7","author":"Grannan","year":"2016","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/bs.apha.2019.05.001_bb0405","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1124\/jpet.105.090134","article-title":"Persistent binding and functional antagonism by xanomeline at the muscarinic M5 receptor","volume":"315","author":"Grant","year":"2005","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.apha.2019.05.001_bb0410","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia?","volume":"153","author":"Green","year":"1996","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb0415","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.schres.2004.09.009","article-title":"Longitudinal studies of cognition and functional outcome in schizophrenia: Implications for MATRICS","volume":"72","author":"Green","year":"2004","journal-title":"Schizophrenia Research"},{"issue":"5","key":"10.1016\/bs.apha.2019.05.001_bb0420","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/adb.12567","article-title":"Selective inhibition of M5 muscarinic acetylcholine receptors attenuates cocaine self-administration in rats","volume":"23","author":"Gunter","year":"2017","journal-title":"Addiction Biology"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb0425","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/cne.902620109","article-title":"The origins of cholinergic and other subcortical afferents to the thalamus in the rat","volume":"262","author":"Hallanger","year":"1987","journal-title":"The Journal of Comparative Neurology"},{"issue":"3","key":"10.1016\/bs.apha.2019.05.001_bb0430","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1755-3768.1984.tb08429.x","article-title":"Toxic effect of scopolamine eye drops in children","volume":"62","author":"Hamborg-Petersen","year":"1984","journal-title":"Acta Ophthalmologica"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb0435","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nn.4173","article-title":"Mesolimbic dopamine signals the value of work","volume":"19","author":"Hamid","year":"2016","journal-title":"Nature Neuroscience"},{"issue":"10","key":"10.1016\/bs.apha.2019.05.001_bb0440","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.biopsych.2017.04.020","article-title":"Association between substance use disorder and polygenic liability to schizophrenia","volume":"82","author":"Hartz","year":"2017","journal-title":"Biological Psychiatry"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb0445","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/0006-8993(93)90268-R","article-title":"Muscarinic and nicotinic receptor changes in the cortex and thalamus of brains of chronic alcoholics","volume":"620","author":"Hellstrom-Lindahl","year":"1993","journal-title":"Brain Research"},{"issue":"5","key":"10.1016\/bs.apha.2019.05.001_bb0450","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1523\/JNEUROSCI.14-05-03351.1994","article-title":"Distribution of m1-m4 muscarinic receptor proteins in the rat striatum: Light and electron microscopic immunocytochemistry using subtype-specific antibodies","volume":"14","author":"Hersch","year":"1994","journal-title":"The Journal of Neuroscience"},{"issue":"3","key":"10.1016\/bs.apha.2019.05.001_bb0455","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: Version III\u2014The final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/bs.apha.2019.05.001_bb0460","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.drugalcdep.2018.07.011","article-title":"Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990\u20132017: Systematic review and meta-analysis","volume":"191","author":"Hunt","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/bs.apha.2019.05.001_bb0465","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/(SICI)1098-2396(199712)27:4<357::AID-SYN9>3.0.CO;2-B","article-title":"Differential expression of D1 and D2 dopamine and m4 muscarinic acetylcholine receptor proteins in identified striatonigral neurons","volume":"27","author":"Ince","year":"1997","journal-title":"Synapse"},{"key":"10.1016\/bs.apha.2019.05.001_bb0470","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1176\/ajp.130.12.1370","article-title":"Antagonistic effects of physostigmine and methylphenidate in man","volume":"130","author":"Janowsky","year":"1973","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"10.1016\/bs.apha.2019.05.001_bb0475","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1523\/JNEUROSCI.3843-09.2010","article-title":"A subpopulation of neuronal M4 muscarinic acetylcholine receptors plays a critical role in modulating dopamine-dependent behaviors","volume":"30","author":"Jeon","year":"2010","journal-title":"The Journal of Neuroscience"},{"issue":"3","key":"10.1016\/bs.apha.2019.05.001_bb0480","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1017\/S0033291700047942","article-title":"Adverse effects of anticholinergic medication on positive schizophrenic symptoms","volume":"13","author":"Johnstone","year":"1983","journal-title":"Psychological Medicine"},{"issue":"41","key":"10.1016\/bs.apha.2019.05.001_bb0485","doi-asserted-by":"crossref","first-page":"10422","DOI":"10.1523\/JNEUROSCI.1850-08.2008","article-title":"Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats","volume":"28","author":"Jones","year":"2008","journal-title":"Journal of Neuroscience"},{"issue":"10","key":"10.1016\/bs.apha.2019.05.001_bb0490","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/npp.2011.199","article-title":"Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia","volume":"37","author":"Jones","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.apha.2019.05.001_bb0495","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.bbr.2017.04.023","article-title":"Effects of muscarinic receptor antagonists on cocaine discrimination in wild-type mice and in muscarinic receptor M1, M2, and M4 receptor knockout mice","volume":"329","author":"Joseph","year":"2017","journal-title":"Behavioural Brain Research"},{"issue":"2","key":"10.1016\/bs.apha.2019.05.001_bb0500","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1601-183X.2010.00663.x","article-title":"Association of CHRM2 polymorphisms with severity of alcohol dependence","volume":"10","author":"Jung","year":"2010","journal-title":"Genes, Brain and Behavior"},{"key":"10.1016\/bs.apha.2019.05.001_bb0505","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrn2515","article-title":"The glutamate homeostasis hypothesis of addiction","volume":"10","author":"Kalivas","year":"2009","journal-title":"Nature Reviews Neuroscience"},{"issue":"5","key":"10.1016\/bs.apha.2019.05.001_bb0510","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2174\/138620708784534824","article-title":"Functional selectivity in GPCR modulator screening","volume":"11","author":"Kenakin","year":"2008","journal-title":"Combinatorial Chemistry & High Throughput Screening"},{"issue":"4","key":"10.1016\/bs.apha.2019.05.001_bb0515","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0022-3956(95)00023-X","article-title":"Slow-wave sleep and symptomatology in schizophrenia and related psychotic disorders","volume":"29","author":"Keshavan","year":"1995","journal-title":"Journal of Psychiatric Research"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-9964(00)00059-1","article-title":"Physostigmine and cognition in schizotypal personality disorder","volume":"48","author":"Kirrane","year":"2001","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1016\/bs.apha.2019.05.001_bb0525","first-page":"529","article-title":"Delta power in sleep in relation to neuropsychological performance in healthy subjects and schizophrenia patients","volume":"18","author":"Koch","year":"2014","journal-title":"The Journal of Neuropsychiatry and Clinical Neurosciences"},{"key":"10.1016\/bs.apha.2019.05.001_bb0530","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1756-6606-5-10","article-title":"M4 muscarinic receptor knockout mice display abnormal social behavior and decreased prepulse inhibition","volume":"5","author":"Koshimizu","year":"2012","journal-title":"Molecular Brain"},{"key":"10.1016\/bs.apha.2019.05.001_bb0535","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrn3877","article-title":"Intrinsic plasticity: An emerging player in addiction","volume":"16","author":"Kourrich","year":"2015","journal-title":"Nature Reviews Neuroscience"},{"key":"10.1016\/bs.apha.2019.05.001_bb0540","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.euroneuro.2018.11.1105","article-title":"Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis","volume":"29","author":"Krause","year":"2019","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/bs.apha.2019.05.001_bb0545","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature10867","article-title":"Structure and dynamics of the M3 muscarinic acetylcholine receptor","volume":"482","author":"Kruse","year":"2012","journal-title":"Nature"},{"issue":"7","key":"10.1016\/bs.apha.2019.05.001_bb0550","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrd4295","article-title":"Muscarinic acetylcholine receptors: Novel opportunities for drug development","volume":"13","author":"Kruse","year":"2014","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/bs.apha.2019.05.001_bb0555","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/323411a0","article-title":"Cloning, sequencing, and expression of complementary DNA encoding the muscarinic acetylcholine receptor","volume":"323","author":"Kubo","year":"1986","journal-title":"Nature"},{"issue":"2","key":"10.1016\/bs.apha.2019.05.001_bb0560","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0014-5793(86)81144-9","article-title":"Primary structure of porcine cardiac muscarinic acetylcholine receptor deduced from the cDNA sequence","volume":"209","author":"Kubo","year":"1986","journal-title":"FEBS Letters"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb0565","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/BF02245249","article-title":"Extrapyramidal side effects of clozapine and haloperidol","volume":"118","author":"Kurz","year":"1995","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/bs.apha.2019.05.001_bb0570","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.neuron.2011.03.025","article-title":"Projection-specific modulation of dopamine neuron synapses by aversive and rewarding stimuli","volume":"70","author":"Lammel","year":"2011","journal-title":"Neuron"},{"issue":"7423","key":"10.1016\/bs.apha.2019.05.001_bb0575","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nature11527","article-title":"Input-specific control of reward and aversion in the ventral tegmental area","volume":"491","author":"Lammel","year":"2012","journal-title":"Nature"},{"key":"10.1016\/bs.apha.2019.05.001_bb0580","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1124\/mol.105.017814","article-title":"Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M1 receptor: Direct pharmacological evidence that AC-42 is an allosteric agonist","volume":"69","author":"Langmead","year":"2006","journal-title":"Molecular Pharmacology"},{"issue":"2","key":"10.1016\/bs.apha.2019.05.001_bb0585","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.pharmthera.2007.09.009","article-title":"Muscarinic acetylcholine receptors as CNS drug targets","volume":"117","author":"Langmead","year":"2008","journal-title":"Pharmacology and Therapeutics"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb0590","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1124\/mol.65.1.257","article-title":"Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: Receptor subtype selectivity via cooperativity rather than affinity","volume":"65","author":"Lazareno","year":"2004","journal-title":"Molecular Pharmacology"},{"issue":"4","key":"10.1016\/bs.apha.2019.05.001_bb0595","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/npp.2009.194","article-title":"Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties","volume":"35","author":"Leach","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/bs.apha.2019.05.001_bb0600","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1021\/cn900003h","article-title":"Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M1 receptor function in the central nervous system","volume":"1","author":"Lebois","year":"2010","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/bs.apha.2019.05.001_bb0605","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0024-3205(93)90300-R","article-title":"Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain","volume":"52","author":"Levey","year":"1993","journal-title":"Life Sciences"},{"issue":"5","key":"10.1016\/bs.apha.2019.05.001_bb0610","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1523\/JNEUROSCI.15-05-04077.1995","article-title":"Expression of ml-m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation","volume":"15","author":"Levey","year":"1995","journal-title":"The Journal of Neuroscience"},{"issue":"10","key":"10.1016\/bs.apha.2019.05.001_bb0615","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1523\/JNEUROSCI.11-10-03218.1991","article-title":"Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies","volume":"1","author":"Levey","year":"1991","journal-title":"The Journal of Neuroscience"},{"issue":"9","key":"10.1016\/bs.apha.2019.05.001_bb0620","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2217\/pgs-2016-0028","article-title":"African-specific variability in the acetylcholine muscarinic receptor M4: Association with cocaine and heroin addiction","volume":"17","author":"Levran","year":"2016","journal-title":"Pharmacogenomics"},{"key":"10.1016\/bs.apha.2019.05.001_bb0625","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.2174\/1568026616666160608084834","article-title":"Dopamine targeting drugs for the treatment of schizophrenia: Past, present and future","volume":"16","author":"Li","year":"2016","journal-title":"Current Topics in Medicinal Chemistry"},{"key":"10.1016\/bs.apha.2019.05.001_bb0630","first-page":"28","article-title":"Distribution of m2 muscarinic receptors in rat brain using antisera selective for m2 receptors","volume":"40","author":"Li","year":"1991","journal-title":"Molecular Pharmacology"},{"issue":"2","key":"10.1016\/bs.apha.2019.05.001_bb0635","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000072880","article-title":"Association of muscarinic m1 receptor genetic polymorphisms with psychiatric symptoms and cognitive function in schizophrenic patients","volume":"48","author":"Liao","year":"2003","journal-title":"Neuropsychobiology"},{"issue":"25","key":"10.1016\/bs.apha.2019.05.001_bb0640","doi-asserted-by":"crossref","first-page":"11642","DOI":"10.1073\/pnas.92.25.11642","article-title":"Identification of a receptor\/G-protein contact site critical for signaling specificity and G-protein activation","volume":"92","author":"Liu","year":"1995","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10.1016\/bs.apha.2019.05.001_bb0645","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00439-006-0229-7","article-title":"Gene-based analysis suggests association of the nicotinic acetylcholine receptor \u03b21 subunit (CHRNB1) and M1 muscarinic acetylcholine receptor (CHRM1) with vulnerability for nicotine dependence","volume":"120","author":"Lou","year":"2006","journal-title":"Human Genetics"},{"key":"10.1016\/bs.apha.2019.05.001_bb0650","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev-neuro-070815-013920","article-title":"The emergence of a circuit model for addiction","volume":"39","author":"Luscher","year":"2016","journal-title":"Annual Review of Neuroscience"},{"issue":"3","key":"10.1016\/bs.apha.2019.05.001_bb0655","first-page":"177","article-title":"Animal models of substance abuse and addiction: Implications for science, animal welfare, and society","volume":"60","author":"Lynch","year":"2010","journal-title":"Comparative Medicine"},{"issue":"37","key":"10.1016\/bs.apha.2019.05.001_bb0660","doi-asserted-by":"crossref","first-page":"15950","DOI":"10.1073\/pnas.0900903106","article-title":"Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation","volume":"106","author":"Ma","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb0665","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.pbb.2008.06.023","article-title":"Antipsychotic property of a muscarinic receptor agonist in animal models for schizophrenia","volume":"91","author":"Maehara","year":"2008","journal-title":"Pharmacology Biochemistry and Behavior"},{"key":"10.1016\/bs.apha.2019.05.001_bb0670","first-page":"1","article-title":"Genetic risk for schizophrenia is associated with substance use in emerging adulthood: An event-level polygenic prediction model","author":"Mallard","year":"2018","journal-title":"Psychological Medicine"},{"key":"10.1016\/bs.apha.2019.05.001_bb0675","doi-asserted-by":"crossref","first-page":"11465","DOI":"10.1073\/pnas.95.19.11465","article-title":"Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-d-aspartate (NMDA) receptor currents in hippocampal pyramidal cells","volume":"95","author":"Marino","year":"1998","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.apha.2019.05.001_bb0680","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.neuroscience.2013.10.062","article-title":"Self administration of oxycodone by adolescent and adult mice affects striatal neurotransmitter receptor gene expression","volume":"258","author":"Mayer-Blackwell","year":"2014","journal-title":"Neuroscience"},{"issue":"Suppl. 1","key":"10.1016\/bs.apha.2019.05.001_bb0685","first-page":"20","article-title":"A double-blind crossover comparison of antiparkinson drug therapy: Amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function","volume":"48","author":"McEvoy","year":"1987","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/bs.apha.2019.05.001_bb0690","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/0278-5846(86)90021-7","article-title":"Positron emission tomography and the possible origins of cytopathology in Alzheimer's disease","volume":"10","author":"McGeer","year":"1986","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"issue":"6","key":"10.1016\/bs.apha.2019.05.001_bb0695","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.bmcl.2017.02.020","article-title":"Continued optimization of the M5NAM ML375: Discovery of VU6008667, an M5NAM with high CNS penetration and a desired short half-life in rat for addiction studies","volume":"27","author":"McGowan","year":"2017","journal-title":"Bioorganic and Medicinal Chemistry Letters"},{"issue":"4","key":"10.1016\/bs.apha.2019.05.001_bb0700","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/0306-4522(83)90108-2","article-title":"Central cholinergic pathways in the rat: An overview based on an alternative nomenclature (Ch1\u2013Ch6)","volume":"10","author":"Mesulam","year":"1983","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb0705","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Molecular Psychiatry"},{"issue":"25","key":"10.1016\/bs.apha.2019.05.001_bb0710","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1016\/S0024-3205(99)00188-5","article-title":"Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland","volume":"64","author":"Moriya","year":"1999","journal-title":"Life Sciences"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb0715","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0014-2999(80)90205-8","article-title":"The effects of long-term ethanol on brain receptors for dopamine, acetylcholine, serotonin and noradrenaline","volume":"65","author":"Muller","year":"1980","journal-title":"European Journal of Pharmacology"},{"issue":"3","key":"10.1016\/bs.apha.2019.05.001_bb0720","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1185\/03007990152673864","article-title":"Focus on clozapine","volume":"17","author":"Naheed","year":"2001","journal-title":"Current Medical Research and Opinion"},{"issue":"25","key":"10.1016\/bs.apha.2019.05.001_bb0725","doi-asserted-by":"crossref","first-page":"19012","DOI":"10.1074\/jbc.M110.125096","article-title":"Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor","volume":"285","author":"Nawaratne","year":"2010","journal-title":"The Journal of Biological Chemistry"},{"issue":"11","key":"10.1016\/bs.apha.2019.05.001_bb0730","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/nn1578","article-title":"Is there a common molecular pathway for addiction?","volume":"8","author":"Nestler","year":"2005","journal-title":"Nature Neuroscience"},{"issue":"8","key":"10.1016\/bs.apha.2019.05.001_bb0735","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s00127-015-1025-2","article-title":"Substance use disorders in schizophrenia, bipolar disorder, and depressive illness: A registry-based study","volume":"50","author":"Nesv\u00e5g","year":"2015","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"key":"10.1016\/bs.apha.2019.05.001_bb0740","first-page":"890","article-title":"Transfected muscarinic acetyicholine receptors selectively couple to Gi-type G proteins and Gq\/11","volume":"45","author":"Offermanns","year":"1994","journal-title":"Molecular Pharmacology"},{"issue":"6","key":"10.1016\/bs.apha.2019.05.001_bb0745","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0022-3956(99)00029-1","article-title":"NMDA receptor hypofunction model of schizophrenia","volume":"33","author":"Olney","year":"1999","journal-title":"Journal of Psychiatric Research"},{"issue":"22","key":"10.1016\/bs.apha.2019.05.001_bb0750","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1001\/jama.1982.03320470029019","article-title":"Transdermal scopolamine psychosis","volume":"247","author":"Osterholm","year":"1982","journal-title":"The Journal of the American Medical Association"},{"issue":"4","key":"10.1016\/bs.apha.2019.05.001_bb0755","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1021\/cn500003z","article-title":"M4 mAChR-mediated modulation of glutamatergic transmission at corticostriatal synapses","volume":"5","author":"Pancani","year":"2014","journal-title":"ACS Chemical Neuroscience"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb0760","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0021-9258(18)52467-4","article-title":"Reconstitutively active G protein-coupled receptors purified from baculovirus-infected insect cells","volume":"266","author":"Parker","year":"1991","journal-title":"Journal of Biological Chemistry"},{"issue":"4","key":"10.1016\/bs.apha.2019.05.001_bb0765","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/334434a0","article-title":"Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes","volume":"334","author":"Peralta","year":"1988","journal-title":"Nature"},{"issue":"8","key":"10.1016\/bs.apha.2019.05.001_bb0770","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0006-3223(00)01017-9","article-title":"The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex","volume":"49","author":"Perry","year":"2001","journal-title":"Biological Psychiatry"},{"issue":"2","key":"10.1016\/bs.apha.2019.05.001_bb0775","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/0006-8993(83)90145-2","article-title":"Individual cells in the nucleus basalis-diagonal band complex have restricted axonal projections to the cerebral cortex in the rat","volume":"269","author":"Price","year":"1983","journal-title":"Brain Research"},{"issue":"10","key":"10.1016\/bs.apha.2019.05.001_bb0780","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00702-012-0817-8","article-title":"Evaluating the links between schizophrenia and sleep and circadian rhythm disruption","volume":"119","author":"Pritchett","year":"2012","journal-title":"Journal of Neural Transmission"},{"key":"10.1016\/bs.apha.2019.05.001_bb0785","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.2147\/NDT.S45963","article-title":"Role of nucleus accumbens glutamatergic plasticity in drug addiction","volume":"9","author":"Quintero","year":"2013","journal-title":"Neuropsychiatric Disease and Treatment"},{"issue":"3","key":"10.1016\/bs.apha.2019.05.001_bb0790","first-page":"491","article-title":"Effects of ethanol administration and withdrawal on neurotransmitter receptor systems in C57 mice","volume":"213","author":"Rabin","year":"1980","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.apha.2019.05.001_bb0795","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/sj.mp.4001924","article-title":"Towards a muscarinic hypothesis of schizophrenia","volume":"12","author":"Raedler","year":"2007","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/bs.apha.2019.05.001_bb0800","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3389\/fnins.2014.00426","article-title":"Nicotinic receptor modulation to treat alcohol and drug dependence","volume":"8","author":"Rahman","year":"2015","journal-title":"Frontiers in Neuroscience"},{"issue":"9","key":"10.1016\/bs.apha.2019.05.001_bb0805","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1021\/acschemneuro.8b00131","article-title":"A novel M1 PAM VU0486846 exerts efficacy in cognition models without displaying agonist activity or cholinergic toxicity","volume":"9","author":"Rook","year":"2018","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/bs.apha.2019.05.001_bb0810","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0304-3940(00)01011-9","article-title":"Localization of M2 muscarinic acetylcholine receptor protein in cholinergic and non-cholinergic terminals in rat hippocampus","volume":"284","author":"Rouse","year":"2000","journal-title":"Neuroscience Letters"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb0815","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0306-4522(97)00681-7","article-title":"Differential presynaptic and postsynaptic expression of m1\u2013m4 muscarinic acetylcholine receptors at the perforant pathway\/granule cell synapse","volume":"86","author":"Rouse","year":"1998","journal-title":"Neuroscience"},{"key":"10.1016\/bs.apha.2019.05.001_bb0820","first-page":"145","article-title":"The effects of scopolamine on working memory in healthy young volunteers","volume":"96","author":"Rusted","year":"1988","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.apha.2019.05.001_bb0825","article-title":"Cognitive functions associated with developing prefrontal cortex during adolescence and developmental neuropsychiatric disorders","author":"Sakurai","year":"2018","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/bs.apha.2019.05.001_bb0830","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1038\/npp.2009.41","article-title":"Altered M1 muscarinic acetylcholine receptor (CHRM1)-G\u03b1q\/11 coupling in a schizophrenia endophenotype","volume":"34","author":"Salah-Uddin","year":"2009","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/bs.apha.2019.05.001_bb0835","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.neuron.2012.10.021","article-title":"The mysterious motivational functions of mesolimbic dopamine","volume":"76","author":"Salamone","year":"2012","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/bs.apha.2019.05.001_bb0840","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/cne.902530302","article-title":"Cholinergic neurons of the laterodorsal tegmental nucleus: Efferent and afferent connections","volume":"253","author":"Satoh","year":"1986","journal-title":"The Journal of Comparative Neurology"},{"issue":"11","key":"10.1016\/bs.apha.2019.05.001_bb0845","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/mp.2008.28","article-title":"Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia","volume":"14","author":"Scarr","year":"2009","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/bs.apha.2019.05.001_bb0850","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1038\/tp.2013.3","article-title":"Decreased cortical muscarinic M1 receptors in schizophrenia are associated with changes in gene promoter methylation, mRNA and gene targeting microRNA","volume":"3","author":"Scarr","year":"2013","journal-title":"Translational Psychiatry"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb0855","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.schres.2012.02.011","article-title":"Muscarinic M1 receptor sequence: Preliminary studies on its effects on cognition and expression","volume":"138","author":"Scarr","year":"2012","journal-title":"Schizophrenia Research"},{"issue":"10","key":"10.1016\/bs.apha.2019.05.001_bb0860","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.biopsych.2006.08.050","article-title":"Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia","volume":"61","author":"Scarr","year":"2007","journal-title":"Biological \u200aPsychiatry"},{"issue":"1\u20133","key":"10.1016\/bs.apha.2019.05.001_bb0865","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.schres.2013.01.023","article-title":"Cholinergic muscarinic M4 receptor gene polymorphisms: A potential risk factor and pharmacogenomic marker for schizophrenia","volume":"146","author":"Scarr","year":"2013","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1016\/bs.apha.2019.05.001_bb0870","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00213-011-2225-4","article-title":"Increased cocaine self-administration in M4 muscarinic acetylcholine receptor knockout mice","volume":"216","author":"Schmidt","year":"2011","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/bs.apha.2019.05.001_bb0875","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0306-4522(02)00665-6","article-title":"Muscarinic receptor antagonism in the basolateral amygdala blocks acquisition of cocaine-stimulus association in a model of relapse to cocaine-seeking behavior in rats","volume":"117","author":"See","year":"2003","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/bs.apha.2019.05.001_bb0880","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/0306-4522(90)90058-C","article-title":"Single cholinergic mesopontine tegmental neurons project to both the pontine reticular formation and the thalamus in the rat","volume":"38","author":"Semba","year":"1990","journal-title":"Neuroscience"},{"issue":"8","key":"10.1016\/bs.apha.2019.05.001_bb0885","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"American Journal of Psychiatry"},{"issue":"45","key":"10.1016\/bs.apha.2019.05.001_bb0890","doi-asserted-by":"crossref","first-page":"14271","DOI":"10.1523\/JNEUROSCI.3930-09.2009","article-title":"A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning","volume":"29","author":"Shirey","year":"2009","journal-title":"Journal of Neuroscience"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb0895","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nchembio.2007.55","article-title":"An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission","volume":"4","author":"Shirey","year":"2008","journal-title":"Nature Chemical Biology"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb0900","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1017\/S0033291700012964","article-title":"Anticholinergic-neuroleptic antagonism in terms of positive and negative symptoms of schizophrenia: Implications for psychobiological subtyping","volume":"17","author":"Singh","year":"1987","journal-title":"Psychological Medicine"},{"issue":"6","key":"10.1016\/bs.apha.2019.05.001_bb0905","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1124\/mol.61.6.1297","article-title":"Discovery of an ectopic activation site on the M1 muscarinic receptor","volume":"61","author":"Spalding","year":"1989","journal-title":"Molecular Pharmacology"},{"issue":"11","key":"10.1016\/bs.apha.2019.05.001_bb0910","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0166-2236(99)01447-2","article-title":"The dopamine hypothesis of reward: Past and current status","volume":"22","author":"Spanagel","year":"1999","journal-title":"Trends in Neurosciences"},{"key":"10.1016\/bs.apha.2019.05.001_bb0915","series-title":"Sleep, neuronal plasticity, and brain function","first-page":"433","article-title":"Sleep and plasticity in schizophrenia","author":"Sprecher","year":"2015"},{"key":"10.1016\/bs.apha.2019.05.001_bb0920","first-page":"782","article-title":"The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat","volume":"299","author":"Stanhope","year":"2001","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"3","key":"10.1016\/bs.apha.2019.05.001_bb0925","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00213-006-0621-y","article-title":"Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors: Functional receptor-binding and in vivo electrophysiological studies","volume":"190","author":"Stark","year":"2007","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1016\/bs.apha.2019.05.001_bb0930","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027538","article-title":"M5 muscarinic receptors mediate striatal dopamine activation by ventral tegmental morphine and pedunculopontine stimulation in mice","volume":"6","author":"Steidl","year":"2011","journal-title":"PLoS One"},{"issue":"September","key":"10.1016\/bs.apha.2019.05.001_bb0935","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neubiorev.2017.09.022","article-title":"Opioid-induced rewards, locomotion, and dopamine activation: A proposed model for control by mesopontine and rostromedial tegmental neurons","volume":"83","author":"Steidl","year":"2017","journal-title":"Neuroscience and Biobehavioral Reviews"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb0940","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1124\/jpet.108.144824","article-title":"M5 muscarinic receptor knockout mice show reduced morphine-induced locomotion but increased locomotion after cholinergic antagonism in the ventral tegmental area","volume":"328","author":"Steidl","year":"2009","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"3","key":"10.1016\/bs.apha.2019.05.001_bb0945","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00213-017-4797-0","article-title":"Effects of muscarinic M1 and M4 acetylcholine receptor stimulation on extinction and reinstatement of cocaine seeking in male mice, independent of extinction learning","volume":"235","author":"Stoll","year":"2018","journal-title":"Psychopharmacology"},{"issue":"23","key":"10.1016\/bs.apha.2019.05.001_bb0950","doi-asserted-by":"crossref","first-page":"13674","DOI":"10.1073\/pnas.1835612100","article-title":"N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity","volume":"100","author":"Sur","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb0955","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0920-9964(91)90006-D","article-title":"Muscarinic cholinergic hyperactivity in schizophrenia: Relationship to positive and negative symptoms","volume":"4","author":"Tandon","year":"1991","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb0960","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0306-4522(03)00513-X","article-title":"Localization of the m5 muscarinic cholinergic receptor in rat circle of Willis and pial arteries","volume":"122","author":"Tayebati","year":"2003","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/bs.apha.2019.05.001_bb0965","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1517\/13543784.2013.750650","article-title":"Assessing the prospect of donepezil in improving cognitive impairment in patients with schizophrenia","volume":"22","author":"Thakurathi","year":"2013","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"3","key":"10.1016\/bs.apha.2019.05.001_bb0970","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1124\/jpet.109.162057","article-title":"Attenuation of cocaine's reinforcing and discriminative stimulus effects via muscarinic M1 acetylcholine receptor stimulation","volume":"332","author":"Thomsen","year":"2010","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"3","key":"10.1016\/bs.apha.2019.05.001_bb0975","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00213-013-3256-9","article-title":"Acute and chronic effects of the M1\/M4-preferring muscarinic agonist xanomeline on cocaine vs. food choice in rats","volume":"231","author":"Thomsen","year":"2014","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/bs.apha.2019.05.001_bb0980","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00213-011-2516-9","article-title":"Contribution of both M1 and M4 receptors to muscarinic agonist-mediated attenuation of the cocaine discriminative stimulus in mice","volume":"220","author":"Thomsen","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.apha.2019.05.001_bb0985","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.neuropharm.2017.09.011","article-title":"Physiological roles of CNS muscarinic receptors gained from knockout mice","volume":"136","author":"Thomsen","year":"2018","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/bs.apha.2019.05.001_bb0990","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00213-009-1740-z","article-title":"Modulation of prepulse inhibition through both M1 and M4 muscarinic receptors in mice","volume":"208","author":"Thomsen","year":"2010","journal-title":"Psychopharmacology"},{"issue":"36","key":"10.1016\/bs.apha.2019.05.001_bb0995","doi-asserted-by":"crossref","first-page":"8141","DOI":"10.1523\/JNEUROSCI.2077-05.2005","article-title":"Reduced cocaine self-administration in muscarinic M5 acetylcholine receptor-deficient mice","volume":"25","author":"Thomsen","year":"2005","journal-title":"The Journal of Neuroscience"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb1000","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00213-006-0682-y","article-title":"Decreased prepulse inhibition and increased sensitivity to muscarinic, but not dopaminergic drugs in M5 muscarinic acetylcholine receptor knockout mice","volume":"192","author":"Thomsen","year":"2007","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb1005","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00127-015-1104-4","article-title":"Prevalence of substance use disorders in psychiatric patients: A nationwide Danish population-based study","volume":"51","author":"Toftdahl","year":"2016","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"key":"10.1016\/bs.apha.2019.05.001_bb1010","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1161\/01.RES.70.2.234","article-title":"Differential muscarinic receptor mRNA expression by freshly isolated and cultured bovine aortic endothelial cells","volume":"70","author":"Tracey","year":"1992","journal-title":"Circulation Research"},{"issue":"12","key":"10.1016\/bs.apha.2019.05.001_bb1015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fj.04-1575fje","article-title":"M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: Relevance to the pathophysiology and treatment of related central nervous system pathologies","volume":"18","author":"Tzavara","year":"2004","journal-title":"The FASEB Journal"},{"issue":"2","key":"10.1016\/bs.apha.2019.05.001_bb1020","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1073\/pnas.1423136112","article-title":"Optogenetic activation of cholinergic neurons in the PPT or LDT induces REM sleep","volume":"112","author":"Van Dort","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.apha.2019.05.001_bb1025","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3389\/fncel.2014.00466","article-title":"Glutamatergic synaptic plasticity in the mesocorticolimbic system in addiction","volume":"8","author":"van Huijstee","year":"2015","journal-title":"Frontiers in Cellular Neuroscience"},{"issue":"4","key":"10.1016\/bs.apha.2019.05.001_bb1030","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/00002093-199812000-00010","article-title":"Efficacy of xanomeline in Alzheimer disease: Cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB)","volume":"12","author":"Veroff","year":"1998","journal-title":"Alzheimer Disease and Associated Disorders"},{"issue":"2","key":"10.1016\/bs.apha.2019.05.001_bb1035","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0304-3940(90)90064-G","article-title":"Localization of m5 muscarinic receptor mRNA in rat brain examined by in situ hybridization histochemistry","volume":"114","author":"Vilar\u00f3","year":"1990","journal-title":"Neuroscience Letters"},{"issue":"1","key":"10.1016\/bs.apha.2019.05.001_bb1040","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0306-4522(91)90181-M","article-title":"Muscarinic cholinergic receptors in the rat caudate-putamen and olfactory tubercle belong predominantly to the m4 class: In situ hybridization and receptor autoradiography evidence","volume":"40","author":"Vilar\u00f3","year":"1991","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/bs.apha.2019.05.001_bb1045","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0306-4522(92)90253-X","article-title":"Muscarinic M2 receptor mRNA expression and receptor binding in cholinergic and non-cholinergic cells in the rat brain: A correlative study using in situ hybridization histochemistry and receptor autoradiography","volume":"47","author":"Vilar\u00f3","year":"1992","journal-title":"Neuroscience"},{"issue":"37","key":"10.1016\/bs.apha.2019.05.001_bb1050","doi-asserted-by":"crossref","first-page":"15037","DOI":"10.1073\/pnas.1010654108","article-title":"Addiction: Beyond dopamine reward circuitry","volume":"108","author":"Volkow","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.apha.2019.05.001_bb1055","first-page":"783","article-title":"Development of an antiserum against m3 muscarinic receptors: Distribution of m3 receptors in rat tissues and clonal cell lines","volume":"40","author":"Wall","year":"1991","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/bs.apha.2019.05.001_bb1060","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/sj.npp.1300502","article-title":"Decreased amphetamine-induced locomotion and improved latent inhibition in mice mutant for the M5 muscarinic receptor gene found in the human 15q schizophrenia region","volume":"29","author":"Wang","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/bs.apha.2019.05.001_bb1065","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1111\/ejn.12279","article-title":"Cholinergic control of morphine-induced locomotion in rostromedial tegmental nucleus versus ventral tegmental area sites","volume":"38","author":"Wasserman","year":"2013","journal-title":"European Journal of Neuroscience"},{"key":"10.1016\/bs.apha.2019.05.001_bb1070","doi-asserted-by":"crossref","first-page":"7050","DOI":"10.1073\/pnas.87.18.7050","article-title":"Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia","volume":"87","author":"Weiner","year":"1990","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"9","key":"10.1016\/bs.apha.2019.05.001_bb1075","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrd2379","article-title":"Muscarinic acetylcholine receptors: Mutant mice provide new insights for drug development","volume":"6","author":"Wess","year":"2007","journal-title":"Nature Reviews Drug Discovery"},{"issue":"12","key":"10.1016\/bs.apha.2019.05.001_bb1080","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1002\/j.1460-2075.1991.tb04941.x","article-title":"Site-directed mutagenesis of the m3 muscarinic receptor: Identification of a series of threonine and tyrosine residues involved in agonist but not antagonist binding","volume":"10","author":"Wess","year":"1991","journal-title":"The EMBO Journal"},{"issue":"27","key":"10.1016\/bs.apha.2019.05.001_bb1085","doi-asserted-by":"crossref","first-page":"19313","DOI":"10.1016\/S0021-9258(18)41776-0","article-title":"Role of conserved threonine and tyrosine residues in acetylcholine binding and muscarinic receptor activation","volume":"267","author":"Wess","year":"1992","journal-title":"The Journal of Biological Chemistry"},{"issue":"5","key":"10.1016\/bs.apha.2019.05.001_bb1090","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.euroneuro.2011.09.003","article-title":"Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels","volume":"22","author":"Weston-Green","year":"2012","journal-title":"European Neuropsychopharmacology"},{"issue":"24","key":"10.1016\/bs.apha.2019.05.001_bb1095","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/0024-3205(89)90111-2","article-title":"Modulation of the lethal effects of cocaine by cholinomimetics","volume":"45","author":"Witkin","year":"1989","journal-title":"Life Sciences"},{"issue":"2","key":"10.1016\/bs.apha.2019.05.001_bb1100","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.bmcl.2016.11.086","article-title":"Challenges in the development of an M4 PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs","volume":"27","author":"Wood","year":"2017","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"1\u20133","key":"10.1016\/bs.apha.2019.05.001_bb1105","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejphar.2008.12.020","article-title":"Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice","volume":"603","author":"Woolley","year":"2009","journal-title":"European Journal of Pharmacology"},{"issue":"24","key":"10.1016\/bs.apha.2019.05.001_bb1110","doi-asserted-by":"crossref","first-page":"14096","DOI":"10.1073\/pnas.251542998","article-title":"Cholinergic dilation of cerebral blood vessels is abolished in M5 muscarinic acetylcholine receptor knockout mice","volume":"98","author":"Yamada","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.apha.2019.05.001_bb1115","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.neuron.2017.12.022","article-title":"Nucleus accumbens subnuclei regulate motivated behavior via direct inhibition and disinhibition of VTA dopamine subpopulations","volume":"97","author":"Yang","year":"2018","journal-title":"Neuron"},{"issue":"2\u20133","key":"10.1016\/bs.apha.2019.05.001_bb1120","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.schres.2005.10.021","article-title":"Clinical significance of sleep EEG abnormalities in chronic schizophrenia","volume":"82","author":"Yang","year":"2006","journal-title":"Schizophrenia Research"},{"issue":"1\u20132","key":"10.1016\/bs.apha.2019.05.001_bb1125","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0006-8993(85)90508-6","article-title":"Cholinergic involvement in lateral hypothalamic rewarding brain stimulation","volume":"329","author":"Yeomans","year":"1985","journal-title":"Brain Research"},{"key":"10.1016\/bs.apha.2019.05.001_bb1130","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-018-0206-2","article-title":"Activation of the mGlu1 metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4 muscarinic receptor allosteric modulators","author":"Yohn","year":"2018","journal-title":"Molecular Psychiatry"},{"issue":"9","key":"10.1016\/bs.apha.2019.05.001_bb1135","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0006-2952(97)00074-9","article-title":"Differential regulation of expression of rat hippocampal muscarinic receptor subtypes following fimbria-fornix lesion","volume":"53","author":"Zang","year":"1997","journal-title":"Biochemical Pharmacology"},{"issue":"3","key":"10.1016\/bs.apha.2019.05.001_bb1140","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/sj.npp.1300367","article-title":"Investigation of M1\/M4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder and major depression disorder","volume":"29","author":"Zavitsanou","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/bs.apha.2019.05.001_bb1145","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1523\/JNEUROSCI.22-05-01709.2002","article-title":"Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice","volume":"22","author":"Zhang","year":"2002","journal-title":"The Journal of Neuroscience"},{"issue":"7","key":"10.1016\/bs.apha.2019.05.001_bb1150","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s00213-013-3306-3","article-title":"Extended access oxycodone self-administration and neurotransmitter receptor gene expression in the dorsal striatum of adult C57BL\/6 J mice","volume":"231","author":"Zhang","year":"2014","journal-title":"Psychopharmacology"},{"issue":"15","key":"10.1016\/bs.apha.2019.05.001_bb1155","doi-asserted-by":"crossref","first-page":"6347","DOI":"10.1523\/JNEUROSCI.22-15-06347.2002","article-title":"Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1-M5 muscarinic receptor knock-out mice","volume":"22","author":"Zhang","year":"2002","journal-title":"The Journal of Neuroscience"},{"issue":"2","key":"10.1016\/bs.apha.2019.05.001_bb1160","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s12264-014-1502-8","article-title":"Prefrontal cortex and the dysconnectivity hypothesis of schizophrenia","volume":"31","author":"Zhou","year":"2015","journal-title":"Neuroscience Bulletin"},{"key":"10.1016\/bs.apha.2019.05.001_bb1165","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fpsyt.2011.00064","article-title":"The dopamine hypothesis of drug addiction and its potential therapeutic value","volume":"2","author":"Diana","year":"2011","journal-title":"Frontiers in Psychiatry"},{"key":"10.1016\/bs.apha.2019.05.001_bb1170","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.104.075887","article-title":"Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats","volume":"312","author":"Jones","year":"2005","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"}],"container-title":["Advances in Pharmacology","Neuropsychotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358919300237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358919300237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T23:25:41Z","timestamp":1610580341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1054358919300237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9780128166680"],"references-count":233,"URL":"https:\/\/doi.org\/10.1016\/bs.apha.2019.05.001","relation":{},"ISSN":["1054-3589"],"issn-type":[{"value":"1054-3589","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}